GlassScriptPhysician profile
Margaret Grifa
NPI 1003020041
$1,426.94
in general payments reported to CMS, 2019-2025
16 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $482 · 2024: $679 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,426.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $289.64 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $261.61 | 2023-2025 | Vraylar |
| Lilly USA, LLC | $233.48 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $219.26 | 2023-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.11 | 2023-2025 | Jardiance, Ofev |
| Exact Sciences Corporation | $87.06 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $52.72 | 2024 | Rexulti |
| Dexcom, INC. | $39.70 | 2024 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.88 | 2024-2025 | Caplyta |
| Sanofi Pasteur INC. | $23.41 | 2023 | |
| Irhythm Technologies, INC. | $21.93 | 2023 | Zio Xt Patch |
| Pfizer INC. | $17.89 | 2024 | |
| Glaxosmithkline, LLC. | $17.23 | 2025 | Shingrix, Arexvy |
| Cequr Corporation | $15.64 | 2024 | Cequr Simplicity |
| Currax Pharmaceuticals LLC | $14.32 | 2023 | Nexlizet, Contrave, Nexletol |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $13.06 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Grifa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.